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The National Committee for Confidential Enquiries 
into Maternal Deaths in South Africa (NCCEMD) has 
issued an alert regarding the continuing high levels 
of maternal deaths due to obstetric haemorrhage, 
the majority of which are judged to be preventable. 
This is especially noted for haemorrhage during and after caesarean 
section (CS).
The preliminary data of the 2011 - 2013 Saving Mothers triennial 
report reveal that obstetric haemorrhage accounted for 684 maternal 
deaths, making it the second most common cause of maternal 
death.[1] There were 221 deaths (32.3%) ascribed to haemorrhage 
associated with CS. This bleeding was detected intraoperatively or 
postoperatively, or was intra-abdominal. Frequently bleeding was 
due to uterine atony secondary to prolonged labour, other causes 
being traumatic extensions of the uterine incision or placental site 
bleeding. Maternal death assessors found over 85% of these deaths to 
be clearly avoidable.
Issues contributing to these deaths
The following major causes have been identified among the cohort of 
the 2011 - 2013 deaths ascribed to haemorrhage:
• Inadequate utilisation of uterotonic agents
• Poor recognition of the severity of the blood loss causing 
hypovolaemia
• Inadequate surgical skill
• Delays in relaparotomy and/or referral in case of post-CS bleeding.
Specific problems with uterotonics
• Poor documentation of whether prophylactic oxytocin was given, 
by what route and in what dosage (there is no designated space on 
the recommended anaesthetic form, the recommended surgery 
form or the anaesthetic assessment tool used by the NCCEMD to 
record oxytocin use)
• Poor documentation of additional uterotonic agents given to treat 
uterine atony, both by the anaesthetist during the surgery and by 
the obstetrician or nurses postoperatively
• Insufficient prophylactic dose of oxytocin at CS (e.g. several cases 
when only a 10 IU oxytocin infusion was given, and several where 
no uterotonic agent was given at all)
• Excessive intravenous (IV) boluses of oxytocin (e.g. 10 IU IV 
bolus)
• Inadequate dosages of therapeutic oxytocin for treatment of 
established intraoperative bleeding due to an atonic uterus (e.g. a 
repeat 2 - 3 IU IV bolus not given, or infusion containing a too-
low concentration of oxytocin administered; 10 IU instead of the 
recommended 20 - 40 IU infusion)
• Infrequent use of ergometrine or oxytocin/ergometrine (Synto-
metrine) as treatment for uterine atony at CS, even in women with 
no contraindication to ergot alkaloids. These agents are of similar 
efficacy to oxytocin and therefore would be expected by inference 
to have superior efficacy to misoprostol.[2] Ergometrine has a 
longer duration of action than oxytocin.[3]
Oxytocin
A key step in avoiding postpartum haemorrhage (PPH) is ensuring 
adequate uterine contraction, as this serves to control bleeding from 
the placental bed naturally.
The mainstay of uterotonic drugs in obstetric practice has been 
oxytocin. However, recently this drug has become a cause for concern 
among anaesthesiologists. The 1997 - 1999 triennial report of the 
Confidential Enquiries into Maternal Deaths in the UK cited the 
administration of 10 IU oxytocin as an IV bolus as the precipitating 
cause of death in two hypovolaemic patients and as contributing 
to the deaths of a number of other patients.[4] This problem was 
noted as contributory in two deaths in the 2005 - 2007 NCCEMD 
report[5] in South Africa (SA) and in another three cases in the 2008 - 
2010 report.[6] A preliminary review of the 2011 - 2013 NCCEMD 
anaesthesia data reveals that the problem is still occurring.
Over-reaction to adverse reports
Anecdotally, there appears to have been a marked over-reaction to 
this information, with a number of medical practitioners avoiding 
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the use of oxytocin entirely. There has been much discussion of 
the NCCEMD findings concerning bleeding at CS in obstetric and 
anaesthetic forums. There is evidence of differences of opinion 
about the use of oxytocin at CS in situations of hypovolaemia and 
hypotension, especially when this situation has arisen as a result of 
bleeding from uterine atony at CS. Obstetricians appear to request 
higher doses of oxytocin to contract the uterus, but anaesthetists 
express reluctance to administer oxytocin because of concern about 
worsening the hypotension. The conflict seems more pronounced 
among junior obstetric doctors and anaesthetists.
An over-reaction to the information of potential harm is 
inappropriate. Oxytocin is still highly beneficial, and administration 
of this drug needs to continue, both intraoperatively and 
postoperatively. Obviously protocol adaptations need to be made to 
ensure that the reported adverse events do not impact on the patient. 
In the situation of hypovolaemic shock, a rapid high-dose IV bolus 
of oxytocin is contraindicated, but an infusion is essential to contract 
the uterus. This should be provided in addition to active fluid, colloid 
and red blood cell concentrate resuscitation, and the concomitant use 
of vasopressors. The obstetric surgeon needs to have the expertise 
to perform surgical measures to reduce bleeding, such as uterine 
compression sutures, if all medical therapy is unsuccessful.
Vasodilation caused by oxytocin
The main adverse effect of oxytocin is hypotension secondary to 
vasodilation. This appears to be mediated by calcium-dependent 
stimulation of nitric oxide release.[3] In animal studies coronary 
vasoconstriction has been demonstrated.[7] Of concern is the 
repeated finding of significant reproducible ST depression on 
the electrocardiogram in pregnant women receiving IV oxytocin 
boluses.[8] The adverse effects appear to be more marked at higher 
bolus doses and with more rapid administration. The cardiovascular 
effects of oxytocin have been well documented and produce a 
clinical picture of peripheral vasodilation, hypotension and increased 
pulmonary artery pressures. Cardiac output is increased by an 
increase in both heart rate and stroke volume.[3] The increase in 
heart rate and stroke volume protects the majority of women from 
adverse outcomes, but clearly points to a group who will be especially 
vulnerable to cardiovascular collapse: those women who cannot 
achieve an increase in cardiac output. This problem is especially 
marked in patients who are already hypovolaemic.
It has been determined that the ED90 effect for uterine myocyte 
stimulation (the dose that can be expected to confer 90% maximal 
contraction) is 0.35 IU in oxytocin-naïve patients at CS[9] and 3.0 
IU in patients who have previously been augmented with oxytocin 
during labour.[10] Another important finding is that the magnitude 
of the hypotensive effect of oxytocin appears to be reduced with the 
administration of repeated doses.[3]
In common with all short-acting drugs (oxytocin has a plasma half-
life of 3 - 20 minutes[11]), administration of larger IV boluses of oxytocin 
to try to prolong effects leads to excessive peaks in concentration, but 
little increase in the duration of action. The solution to this effect is 
repeated smaller boluses, and/or a constant infusion of the drug.
Suggested dosing of oxytocin
These observations suggest that the use of the lowest effective dose 
of oxytocin that produces adequate uterine contraction will improve 
the risk/benefit profile. In the event of inadequate uterine contraction 
after delivery of the baby, the obstetric surgeon should undertake 
the usual physical manoeuvres such as removal of any remaining 
products of conception and manual rubbing up the uterus while 
the anaesthetist administers a repeat bolus of oxytocin (2.5 IU over 
30 seconds). The infusion rate of the oxytocin should be increased 
simultaneously. It is important to ensure that the postoperative 
infusion of oxytocin should not be interrupted in any manner.
It has also been noted that the vasodilatory effect of an oxytocin 
bolus can be countered by administration of a concurrent dose of 
phenylephrine.[12] When administering oxytocin to a hypotensive 
hypovolaemic woman, in addition to the normal resuscitative measures 
of rapid fluid administration it would be appropriate to administer 
phenylephrine 50 - 100 µg as an intravenous infusion (IVI).
Prophylactic use of oxytocin at CS
Recommendations for the routine prophylactic administration of 
oxytocin at CS have previously been issued in SA.[13] These can be 
summarised as prophylactic administration of 2.5 IU oxytocin as 
an IVI over 1 minute, followed by 20 IU in 1 L clear fluid over 8 
hours. In the situation where haemorrhage is occurring, judicious 
administration of increased doses of oxytocin is required. The 
oxytocin infusion regimen may be increased up to the equivalent of 
10 IU/h (80 IU in 1 000 mL fluid at 125 mL/h). Where there is access 
to a syringe driver, this can be achieved by placing 100 IU oxytocin 
in 50 mL saline and running it at 5 mL/h.
Controlled postoperative infusion of oxytocin for at least 8 
hours is the gold standard for the pharmacological prevention of 
PPH after CS. This is especially important if the obstetrician is 
inexperienced.[14] However, it may be difficult to achieve in some 
hospital environments, where care in the wards is erratic and there 
is limited access to labour-saving devices such as rate controllers. 
Mechanical rate controllers (Dial-A-Flo) have been utilised, but are 
dependent on a functioning IVI line and a specific height of the 
attached IVI fluid, while flow rates are not constant when other fluids 
are ‘piggy backed’ onto the IVI line.
Medical practitioners should motivate for mechanical rate-
controlling devices (infusion pumps and syringe drivers) where 
possible. When it is not possible to achieve reliable oxytocin infusion 
for at least 8 hours after CS, the intramuscular administration 
of oxytocin 10 IU 4-hourly or oxytocin/ergometrine 5 IU/0.5 µg 
8-hourly may provide a satisfactory alternative.
Ergometrine
Ergometrine is a uterotonic drug that has received bad publicity, 
firstly because ergometrine is contraindicated when vasoconstriction 
is a major concern (hypertension and cardiac disease), and secondly 
because it has pronounced side-effects such as nausea and emesis. 
However, ergometrine has an alternative mechanism of action to 
either oxytocin or misoprostol, and represents a useful second-line 
agent. The vasoconstrictive action of ergometrine counterbalances 
the vasodilation of oxytocin. Small IV doses of 0.2 mg, building up 
to a maximum total of 0.6 mg, are beneficial. Ergometrine has a long 
duration of action (half-life 120 minutes).[3]
Misoprostol
Misoprostol (Cytotec) has become a popular means of causing 
uterine contraction. It is easy to administer orally, rectally or 
sublingually, and appears benign. However, concerning data have 
been published about adverse effects and worsening outcomes at 
higher doses.[2] While side-effects of pyrexia and tachycardia are 
well documented, misoprostol may be a useful adjunct when used 
in appropriate doses. Since many patients will have received prior 
doses of misoprostol, it is important to check carefully on the total 
dose already administered; sufficient drug should be given to bring 
the total dose up to 600 mg. Anaesthetists find that misoprostol is 
often most conveniently administered sublingually. The fact that it 
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does not require refrigeration is an advantage in the resource-poor 
environment.
Prostaglandin F2-alpha
Prostaglandin F2-alpha is often used as a ‘last line’ of pharma-
cological action. It is very potent, and severe hypertension and 
bronchospasm have been recorded after IV use.[15] Off-label 
intramyometrial injection has been described,[16] but its use should be 
confined to institutions with specialist skills and experience.
Guidance for use of uterotonics
The NCCEMD has produced guidelines on the prevention 
and treatment of blood loss at CS adapted from World Health 
Organi zation guidelines, Royal College of Obstetricians and 
Gynaecologists guidelines and recommendations from obstetric 
anaesthetic experts.[3,17,18] These are found in the monograph of 
management of PPH in SA, which contains algorithms outlining use 
of uterotonic agents.[19] Of note, most international guidelines on 
prevention and treatment of PPH focus on vaginal delivery and do 
not separately specify routes and dosages for CS. There is a need to 
strengthen guidance for use of uterotonics at CS, globally and in SA.
The SA guidelines have been described in a number of publi-
cations,[19,20] and wall posters for use in operating theatres have been 
developed.
The NCCEMD advocates that the problem of mat er nal death be 
approached under the ‘5Cs’:
 
1.   Care – a Commitment to quality
2.   Coverage – ensuring that all woman receive the care they deserve
3.   Caesarean section safety
4.   Contraception
5.   Community involvement.
The suggestions in this article encompass three of these important 
principles.
Commitment to quality
Implement and enforce recognised protocols. Hitherto, the uptake of 
these guidelines and algorithms has not been widespread.
Implement methods of monitoring uteronic administration. The 
recommended monitoring tools have been added to the maternity 
case record charts and the assessment tools used by the confidential 
enquiry processes. Documentation needs to be improved in SA 
hospitals.
Coverage
Effective rollout of guidelines at district level must occur, and 
familiarity with them among the anaesthetic fraternity must increase.
Managers of health facilities conducting CS need to ensure 
availability of the appropriate drugs, and facilities for administration 
of these drugs.
Caesarean section safety
It is very important that anaesthetists, obstetricians and midwives 
achieve consensus on the use of oxytocin and other uterotonics at CS, 
so that uterine atony at CS can be prevented and treated adequately.
Renewed emphasis on these issues needs to be encouraged via 
medical schools, the district clinical specialist teams, the Essential 
Table 1. A stepwise approach to the administration of uterotonics after CS 
Stage
Option 1 (suitable for units equipped with volumetric 
pumps, syringe drivers and trained anaesthetists) Option 2 (suitable for resource-constrained units)
Step 1:
All cases
1.   Oxytocin 2.5 IU IVI slow bolus (over 30 s)
2.   Oxytocin 7.5 IU in remaining IVI fluid running in
3.   Oxytocin infusion 20 IU/1 000 mL at 125 mL/h for 8 h
(125 mL/h is equivalent to 42 drops/min from a ‘20 
dropper’ administration set)
1.   Syntometrine 1 amp IMI in left deltoid after delivery  
of baby (be aware of CIs)
 If CI:
Oxytocin 10 IU IMI in left deltoid after delivery of baby
(repeat at 4 hours in ward)
2.   Oxytocin 20 IU/1 000 mL IVI at 125 mL/h
Step 2:
Ongoing uterine 
atony at 3 minutes
1.   Repeat oxytocin 2.5 IU IVI slow bolus (over 30 s)
2.   Oxytocin infusion 20 IU/1 000 mL at 125 mL/h
Oxytocin 20 IU/1 000 mL IVI at125 mL/h
Step 3:
Actively bleeding 
cases
1.   Ergometrine 0.2 mg IVI slow bolus repeated up to 0.6 mg
 or
 Syntometrine 0.1 mg/L IU IVI slow bolus (over 30 s) 
repeated up to 0.5 mg/5 IU
or
Misoprostol 400 - 600 µg sublingual or rectal (if CI to 
ergometrine)
2.   Oxytocin infusion 40 IU/1 000 mL at 125 mL/h
3.   Tranexamic acid 1 g IVI (may be considered) 
1.   Syntometrine 1 amp IMI or ergometrine 1.0 mg IMI in 
deltoid (if not already administered)
or
Misoprostol 400 - 600 µg sublingual or rectal  
(if CI to ergometrine)
2.  Continue oxytocin infusion
3.   Tranexamic acid 1 g IVI (may be considered if available)
Step 4:
Resistant bleeding 
cases
Consider intramyometrial prostaglandin F2- alpha (dilute 5 mg 
in 10 mL and give 1 mL intramyometrially, can be repeated × 1) 
NB: This table focuses on the use of uterotonic agents for medical management of uterine atony at and after CS. It does not describe the concurrent 
resuscitative measures required for women with excessive bleeding, nor does it cover surgical measures that must be performed following failed 
medical management of uterine atony associated with CS.
IVI = intravenous infusion; IMI = intramuscular injection; CI = contraindication.
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Steps in the Management of Obstetric Emergencies programme and 
the national anaesthesiology and obstetric societies.
Table 1 presents a guideline for a stepwise approach to use of 
uterotonics at CS that has been mutually agreed on between obstet-
ricians and anaesthetists of the NCCEMD and is evidence based.
Conclusion
We strongly recommend roll-out and implementation of these 
guidelines at all SA facilities conducting CS. The continued increase 
in deaths from maternal haemorrhage, particularly after CS, is 
unacceptable. It is the responsibility of the doctors giving the 
anaesthetic, the doctors performing the surgery and the nurses 
performing postoperative monitoring to reduce these deaths.
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